OverviewSuggest Edit

Immunicum is a biopharmaceutical company that develops immune therapies against a range of various tumors. The Company's lead product, ilixadencel, has been developed to be able to take advantage of each patient's own tumor antigen. Immunicum is also engaged in research and development for production of pharmaceuticals.

TypePublic
Founded2002
HQStockholm, SE
Websiteimmunicum.se

Latest Updates

Employees (est.) (Apr 2022)29
Revenue (FY, 2021)KR0
Share Price (May 2022)KR2(+11%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Immunicum

Alex Karlsson-Parra

Alex Karlsson-Parra

Chief Scientific Officer
Helén Tuvesson

Helén Tuvesson

Director
Sven Andreasson

Sven Andreasson

Director
Christine Lind

Christine Lind

Interim Chairman
Show more

Immunicum Office Locations

Immunicum has offices in Stockholm and Leiden
Stockholm, SE (HQ)
Tändstickspalatset, Västra Trädgårdsgatan 15
Leiden, NL
Emmy Noetherweg 2K, 2333 BK
Show all (2)

Immunicum Financials and Metrics

Immunicum Revenue

SEK

Gross profit (FY, 2021)

31.0k

Net income (FY, 2021)

(133.4m)

EBITDA (FY, 2021)

(130.1m)

EBIT (FY, 2021)

(130.1m)

Market capitalization (9-May-2022)

408.8m

Closing stock price (9-May-2022)

2.0

Cash (31-Dec-2021)

155.3m

EV

253.8m
Immunicum's current market capitalization is kr408.8 m.
Annual
SEKFY, 2018FY, 2019FY, 2020FY, 2021

Revenue

16.7m

Gross profit

184.0k16.7m31.0k

R&D expense

(70.7m)(49.0m)(47.9m)(85.8m)
Quarterly
SEKQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Revenue

445.0k2.1m

Gross profit

143.0k76.0k226.0k90.0k1.1m885.0k253.0k24.0k(245.0k)

R&D expense

(23.2m)(25.8m)(23.7m)(23.5m)(17.7m)(16.6m)(29.4m)(21.8m)(14.5m)
Annual
SEKFY, 2018FY, 2019FY, 2020FY, 2021

Cash

443.8m14.0m167.6m155.3m

Prepaid Expenses

2.3m1.1m8.0m10.2m

Inventories

1.5m
Quarterly
SEKQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Cash

393.4m363.4m334.1m263.4m232.2m197.6m119.0m211.7m181.5m

Prepaid Expenses

1.9m4.5m2.6m3.6m7.5m4.6m5.1m7.1m9.6m
Annual
SEKFY, 2018FY, 2019FY, 2020FY, 2021

Net Income

(97.8m)(44.9m)(86.0m)(130.1m)

Accounts Payable

19.6m(3.3m)761.0k10.7m
Quarterly
SEKQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Net Income

(29.1m)(62.3m)(92.0m)(33.9m)(59.0m)(80.7m)(40.8m)(72.1m)(98.4m)

Accounts Payable

(20.9m)(15.0m)(21.2m)(662.0k)7.7m(8.0m)1.1m(1.7m)(6.5m)
Show all financial metrics

Immunicum Revenue Breakdown

Embed Graph

Immunicum revenue breakdown by business segment: 100.0% from PHARMACEUTICAL BIOLOG/VACCINES

Immunicum Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Immunicum Online and Social Media Presence

Embed Graph

Immunicum News and Updates

Immunicum AB: Report from the Annual General Meeting of Immunicum AB (publ) on 10 May 2022

At the annual general meeting (the “AGM”) of Immunicum AB (publ), reg. no 556629-1786, (the “Company”), on 10 May 2022 the AGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions, please refer to the notice to the AGM and the comple…

Immunicum AB: Immunicum Appoints Leopold Bertea as Chief Technology Officer

Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, announced the appointment of Leopold Bertea, PhD, as Chief Technology Officer (CTO), effective as of today, May 5, 2022. In his role as CTO at …

Immunicum AB: Immunicum to Present Preclinical Data Demonstrating Synergy of DCP-001 with Standard Treatments for Acute Myeloid Leukemia

COMBINATION OF CANCER RELAPSE VACCINE CANDIDATE WITH 5’-AZACITIDINE AND VENETOCLAX SHOWS SUPERIOR TUMOR REDUCTION IN AN AML MODEL

Immunicum AB: Immunicum to Participate in Upcoming Conferences

Immunicum AB (publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, today announced its participation in the following upcoming conferences:

Immunicum AB: Immunicum AB (publ) Publishes the Annual Report for 2021

Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, today announced that its Annual Report for 2021 is now available on the Company’s corporate website: www.immunicum.com.
Show more

Immunicum Blogs

Immunicum Corporate Presentation at Redeye Growth Day 2021

On Wednesday, June 2nd, Erik Manting, CEO at Immunicum, presented a corporate overview at the Redeye Growth Day... Read more The post Immunicum Corporate Presentation at Redeye Growth Day 2021 first appeared on Immunicum.

Immunicum Investor Event on April 22, 2021 at 1:00 pm CET

Immunicum will host an Investor Event on April 22, 2021 with introductions and updates by the Executive Management... Read more The post Immunicum Investor Event on April 22, 2021 at 1:00 pm CET first appeared on Immunicum.

Corporate Presentation April

Click here to view our April corporate presentation The post Corporate Presentation April first appeared on Immunicum.

Corporate Presentation – February 2021

Click here to view our most recent corporate presentation: February 2021 Corporate Presentation The post Corporate Presentation - February 2021 first appeared on Immunicum.

Transaction Webcast Presentation

Click here to access the transaction webcast presentation: Transaction Webcast Details The post Transaction Webcast Presentation first appeared on Immunicum.

Transaction Webcast Details

Representatives of Immunicum & DCprime will hold a live webcast on Thursday, November 19th at 8:00 a.m. CET... Read more The post Transaction Webcast Details first appeared on Immunicum.
Show more

Immunicum Frequently Asked Questions

  • When was Immunicum founded?

    Immunicum was founded in 2002.

  • Who are Immunicum key executives?

    Immunicum's key executives are Alex Karlsson-Parra, Helén Tuvesson and Sven Andreasson.

  • How many employees does Immunicum have?

    Immunicum has 29 employees.

  • Who are Immunicum competitors?

    Competitors of Immunicum include SHINKEI Therapeutics, Genexine and Sea4Us.

  • Where is Immunicum headquarters?

    Immunicum headquarters is located at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm.

  • Where are Immunicum offices?

    Immunicum has offices in Stockholm and Leiden.

  • How many offices does Immunicum have?

    Immunicum has 2 offices.